

*Drug Therapy*ALASTAIR J.J. WOOD, M.D., *Editor***TREATMENT OF BREAST CANCER**

GABRIEL N. HORTOBAGYI, M.D.

BREAST cancer is a major public health problem worldwide. Management of breast cancer was last reviewed in the *Journal* in 1992.¹ The accumulation of new biologic information, the results of recent clinical trials, and the availability of new diagnostic and therapeutic tools make it appropriate to review the subject again.

EPIDEMIOLOGY

The incidence of breast cancer in the United States has been increasing gradually for the past three decades.^{2,3} It was estimated that 181,600 new cases of breast cancer were diagnosed in the United States in 1997 and that 44,190 people would die of breast cancer during the same year. However, incidence and mortality have recently leveled off and even decreased slightly.³ Similar decreases in mortality were recently reported in Sweden and the United Kingdom.^{4,5}

The incidence of breast cancer increases with age, although the rate of increase slows after menopause.^{6,7} Early menarche, late menopause, and nulliparity increase the risk of breast cancer. Atypical lobular or ductal hyperplasia also increases the risk, and benign breast disease does so marginally.^{8,9} Other risk factors are early exposure to ionizing radiation, long-term postmenopausal estrogen-replacement therapy, and alcohol consumption. The most important risk factor is a family history of breast cancer.¹⁰⁻¹³ About 5 to 10 percent of all breast cancers occur in high-risk families, and there are several familial breast cancer syndromes, including the breast-ovarian cancer syndrome, the Li-Fraumeni syndrome, and Cowden's disease.¹²

BIOLOGY

The recent identification and cloning of *BRCA1* and *BRCA2* has expanded our knowledge of familial

breast cancer.^{14,15} Germ-line mutations in these two genes are associated with a 50 to 85 percent lifetime risk of breast cancer, ovarian cancer, or both. Tests for these mutations exist, and research efforts to develop comprehensive genetic screening and counseling programs are ongoing.¹⁶ All breast cancers have somatic genetic abnormalities. In sporadic breast cancer, abnormalities have been identified in several genes (including *p53*, *bcl-2*, *c-myc*, and *c-myb*),^{17,18} and in some cancers normal genes or gene products (*HER-2/neu* and cyclin D1) are overexpressed. However, the number and types of mutations necessary for the development of sporadic breast cancer are not known.

Many factors that stimulate or inhibit growth influence the growth and proliferation of breast-cancer cells.¹⁹ Gonadal steroid hormones (estrogens, progestins, and androgens), growth factors (epidermal growth factor, transforming growth factors α and β , and insulin-like growth factors I and II), and various cytokines and lymphokines influence the behavior and phenotypic expression of breast cells. For instance, production of parathyroid hormone-related protein, prostaglandin E, or interleukin-6 by the tumor leads to the development of osseous metastases.²⁰ The recognition that these factors influence the growth and dissemination of breast cancer has provided new targets for therapeutic and preventive intervention.²¹⁻²³ Breast cancer also induces neovascularization, which, in turn, facilitates the metastatic process.²³ Metastatic spread is not a random mechanical phenomenon but requires systematic interaction among breast cells, stroma, and surrounding normal tissue at both primary and metastatic sites.²⁴ Adhesion molecules, local mediators, hormones, and growth factors must all act for metastases to develop. On the basis of this new information, diagnosis and treatment have changed. Many new cytotoxic and hormonal agents have emerged from new biologic concepts and are being developed for clinical use.

DIAGNOSTIC APPROACHES

Systematic screening by means of mammography and clinical examination results in early diagnosis of breast cancer and a 25 to 30 percent decrease in mortality due to breast cancer in women over the age of 50 years (Table 1)²⁵ and probably also in women between the ages of 40 and 50 years.²⁶ The American Cancer Society and the National Cancer Institute recommend annual screening mammography for women older than 40 years who have a standard risk of breast cancer.^{26,27} In women from high-risk families,

From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 56, Houston, TX 77030, where reprint requests should be addressed to Dr. Hortobagyi.
©1998, Massachusetts Medical Society.

TABLE 1. BENEFIT OF SCREENING MAMMOGRAPHY ACCORDING TO AGE.*

STUDY	DURATION OF FOLLOW-UP	SCREENING INTERVAL	RELATIVE RISK OF DEATH FROM CANCER (95% CI)†	
			AGE 50-74 YR	AGE 40-49 YR
			yr	mo
Edinburgh	10	24	0.8 (0.6-1.1)	0.8 (0.5-1.5)
Malmö	12	18-24	0.9 (0.6-1.2)	0.5 (0.2-1.2)
Kopparberg	12	24-33	0.8 (0.5-0.9)	0.8 (0.4-1.4)
Östergötland	12	24-33	0.8 (0.6-1.0)	1.3 (0.8-2.3)
Canada	7	12	1.0 (0.6-1.5)	1.4 (0.8-2.2)
Health Insurance Plan	10	12	0.7 (0.5-1.0)	0.8 (0.5-1.2)
Stockholm	8	28	0.6 (0.4-1.1)	1.0 (0.5-2.0)
Gothenburg	7	18	0.9 (0.5-1.6)	0.7 (0.3-2.0)
Overall	—	—	0.8 (0.7-0.9)	0.9 (0.8-1.1)

*Data are modified from Tables 2 and 3 in Kerlikowske et al.,²⁵ with the permission of the publisher.

†Relative risks are for women who underwent mammographic screening as compared with those who did not. CI denotes confidence interval.

especially those with *BRCA1* or *BRCA2* mutations, screening should start at 25 years of age, or 5 years earlier than the earliest age at which breast cancer was diagnosed in a family member. Substantial technical improvements have been made in screening mammography, and additional improvements are expected to result from digital mammography. Breast magnetic resonance imaging and technetium-99m sestamibi imaging are under evaluation and may further increase our capability for early diagnosis.^{28,29}

Twenty years ago, incisional or excisional biopsies were the standard methods for confirming the diagnosis; today, fine-needle aspiration³⁰ or core needle biopsy³¹ is the standard. Ultrasound-guided core needle biopsy, stereotactic biopsy,³² and magnetic resonance-directed biopsy have become important diagnostic tools, especially for women with suspicious but nonpalpable breast masses. The use of large-core needle-biopsy techniques increases the pathologist's ability to characterize the lesion.³³

THERAPY

Primary Breast Cancer

In some women breast cancer is a local disease without distant spread. Such early breast cancers are usually diagnosed by screening mammography and are highly curable with local or regional treatment alone.³⁴ However, most women with primary breast cancer have subclinical metastases, and in a high percentage of those treated with apparently curative surgery (with or without radiotherapy), distant metastases ultimately develop.^{35,36}

Local and Regional Treatment

Radical mastectomy has been largely discontinued and is seldom, if ever, indicated today.³⁷ Randomized trials have established that for most women with early breast cancer, lumpectomy (wide excision of the tumor with preservation of the breast) with radiotherapy is the preferred treatment (Fig. 1),³⁸ and up to 50 percent of women with early breast cancer in the United States are now treated in this way. However, there are marked geographic variations in the use of this treatment in the United States,³⁹ suggesting that patients' preferences and physicians' choices often override medical criteria in the selection of treatment. Radiotherapy, an integral part of breast-conserving treatment, is inappropriately withheld from some women, especially those older than 65 years.⁴⁰ Noninvasive (in situ) ductal and lobular breast cancer can also be treated adequately with lumpectomy and radiotherapy.^{41,42}

Axillary Lymph-Node Dissection

The probability of recurrence is higher for women with histologically positive axillary lymph nodes and increases with each additional positive node. Axillary lymph-node dissection provides prognostic information but has minimal therapeutic benefit or none, especially in women with clinically negative axillary lymph nodes,⁴³ and it is responsible for most of the morbidity associated with breast surgery. Therefore, there is increasing interest in developing alternative methods to obtain prognostic information. Sentinel-lymph-node mapping is a procedure in which a radioactive substance or a blue dye is injected into the area around the tumor; a short time later, the lower ipsilateral axilla is explored through a small incision and the lymph node that has taken up the dye or radioactive substance (i.e., the sentinel node) is excised.⁴⁴ If it is histologically negative, the rest of the axillary lymph nodes are also likely to be negative. In expert hands, this procedure identifies the sentinel node in more than 90 percent of women. Elsewhere in this issue of the *Journal*, Krag et al. report similar results in a large multicenter trial.⁴⁵ The positive predictive value of a successful sentinel-node biopsy approaches 100 percent, whereas its negative predictive value exceeds 95 percent.^{44,45} Many patients with clinically negative axillary lymph nodes could be spared an axillary dissection if the sentinel node was found to be negative.

An alternative approach is to analyze the primary tumor for nuclear or histologic grade, kinetics of cell growth and division, hormone-receptor expression, markers of invasive or metastatic capability, or blood-vessel content. A combination of these prognostic markers might provide an acceptable substitute for the information derived from axillary lymph-node examination. Until these newer techniques are vali-




Figure 1. Individual and Pooled Odds Ratios for Survival at 10 Years in Women with Breast Cancer Treated by Breast-Conserving Therapy as Compared with Mastectomy.

Breast-conserving therapy consisted of breast-conserving surgery plus radiation. The horizontal bars indicate 95 percent confidence intervals. For the pooled data, the odds ratio is 0.9 (95 percent confidence interval, 0.8 to 1.0). IGR denotes Institut Gustave-Roussy, NSABP National Surgical Adjuvant Breast and Bowel Project, NCI National Cancer Institute, and EORTC European Organization for Research and Treatment of Cancer. Adapted from Fisher,³⁵ with the permission of the publisher.

dated, axillary dissection remains the standard of care for all women with invasive breast cancer or large non-invasive tumors (>2.5 cm).

Radiotherapy

Radiotherapy is an integral part of breast-conserving treatment.^{34,38} A recent randomized trial showed that administering chemotherapy before radiotherapy resulted in higher survival rates when both chemotherapy and radiotherapy were given postoperatively.⁴⁶

Postmastectomy radiotherapy reduces the incidence of local and regional recurrences by 50 to 75 percent, but in most randomized trials, and according to a meta-analysis, this reduction was not accompanied by increased survival.⁴⁷⁻⁵⁰ For that reason and because of its potential for long-term adverse effects, radiotherapy after mastectomy is indicated only for women at high risk for local or regional recurrence (patients with large tumors invading the skin of the breast or the chest wall or those with many positive axillary lymph nodes). However, in two recent, long-term randomized studies of high-risk premenopausal women with breast cancer treated with modern radiotherapy techniques and chemotherapy or with chemotherapy alone, there were fewer local and regional recurrences and overall survival was significantly better among the women treated with radiotherapy and chemotherapy (Table 2).^{51,52} These results have renewed interest in postmastectomy radiotherapy.

TABLE 2. TEN-YEAR CANCER-FREE SURVIVAL AND OVERALL SURVIVAL AMONG WOMEN TREATED WITH CHEMOTHERAPY WITH OR WITHOUT RADIOTHERAPY AFTER MASTECTOMY.

STUDY AND OUTCOME	NO. OF SUBJECTS	PERCENT SURVIVING		P VALUE
		CHEMOTHERAPY	CHEMOTHERAPY AND RADIOTHERAPY	
British Columbia ⁵¹	318			
Cancer-free survival		41	56	0.007
Overall survival		54	64	0.07
Danish Breast Cancer Cooperative Group ⁵²	1708			
Cancer-free survival		34	48	<0.001
Overall survival		45	54	<0.001

Systemic Hormone Therapy or Chemotherapy

The optimal treatment for women with primary breast cancer involves multiple methods and includes systemic therapy with hormonal agents, combination chemotherapy, or both. Over the past 25 years, various aspects of systemic therapy have been studied in many randomized trials, and there have been four overviews of data from the available randomized trials.⁵³⁻⁵⁶ Current knowledge is based on about 400 trials including more than 220,000 women. Hormonal therapy and chemotherapy added to local

treatment favorably alter the natural history of breast cancer. The reduction in the rates of recurrence and death persists beyond 15 years for all forms of systemic treatment. Most women with primary breast cancer have sufficient residual risk after regional therapy to benefit from systemic therapy, but for some the benefit is marginal. The indications for systemic adjuvant therapy are shown in Table 3.

For adjuvant therapy, combination chemotherapy is more effective than single-drug therapy, reducing the annual risk of death by about 20 percent.⁵³ Although the effects of combination chemotherapy are more marked in women younger than 60 years, especially those who are premenopausal when therapy is begun, its effectiveness has been clearly demonstrated up to the age of 69 years. Adjuvant tamoxifen therapy significantly reduces the risks of recurrence and death in women in all age groups. The benefit is greater when tamoxifen is administered for about five years, rather than one to three years, and when it is given to women with estrogen-receptor-positive tumors.⁵⁴ Recent analyses suggest that women with estrogen-receptor-negative tumors should not be treated with hormonal therapy. Treatment for more than five years is no more effective than treatment for five years.⁵⁷

Preoperative Chemotherapy

Chemotherapy is usually administered after surgery in women with operable breast cancer. However, for women with large operable tumors, preoperative chemotherapy may have some advantages. Several reports^{53,58} have indicated that close to 90 percent of primary operable tumors decrease in size by more than 50 percent after chemotherapy, thus making lumpectomy a possibility for many women who would

otherwise have required a mastectomy. In terms of survival, there is no apparent advantage to preoperative chemotherapy as compared with postoperative chemotherapy.

Duration of Chemotherapy

In several trials, combination treatment for less than three months was inferior to treatment for four to six months, whereas treatment with a single combination-chemotherapy regimen, such as cyclophosphamide, methotrexate, and fluorouracil (CMF), for longer than six months was no more effective than treatment for four to six months.^{53,55,59} The combinations used most often are fluorouracil, doxorubicin, and cyclophosphamide (FAC); fluorouracil, epirubicin, and cyclophosphamide (FEC); doxorubicin and cyclophosphamide (AC); and CMF. These combinations are administered intermittently at intervals of three to four weeks. Six cycles of FAC or FEC (duration, 18 to 24 weeks), six cycles of CMF (duration, 18 to 24 weeks), or four cycles of AC (duration, 12 to 16 weeks) are considered standard therapy. A recent report of the preliminary results of a large randomized trial suggested that the addition of four cycles of paclitaxel (duration, 12 to 16 weeks) to four cycles of AC improved both disease-free survival and overall survival rates.⁶⁰ In premenopausal women, ovarian ablation has a substantial benefit, equivalent to that of combination chemotherapy or tamoxifen.^{53,56} This benefit persists for 15 years after treatment.

Combination Chemotherapy and Hormone Therapy

The combination of tamoxifen (or ovarian ablation for premenopausal women) and chemotherapy is more effective than either alone.^{53,55,56,59} Therefore,

TABLE 3. INDICATIONS FOR ADJUVANT SYSTEMIC THERAPY AFTER SURGERY IN WOMEN WITH OPERABLE BREAST CANCER.

TYPE OF DISEASE	ADJUVANT THERAPY INDICATED*
Breast cancer without evidence of invasion	
Noninvasive breast cancer (ductal or lobular carcinoma in situ)	None
Breast cancer with evidence of invasion, but negative axillary lymph nodes	
Microinvasive breast cancer (<1 mm in largest diameter)	None
Invasive ductal or lobular carcinoma <1 cm in largest diameter	None
Invasive carcinoma <3 cm in largest diameter with favorable histologic findings (pure tubular, mucinous, or papillary)	None
Invasive ductal or lobular carcinoma ≥1 cm in largest diameter	Chemotherapy, hormonal therapy, or both
Invasive carcinoma ≥3 cm in largest diameter with favorable histologic findings (pure tubular, mucinous, or papillary)	Chemotherapy, hormonal therapy, or both
Invasive breast cancer with positive axillary lymph nodes	
All tumors, regardless of size or histologic findings	Chemotherapy, hormonal therapy, or both

*Chemotherapy consists of fluorouracil, doxorubicin, and cyclophosphamide (FAC); doxorubicin and cyclophosphamide (AC); or cyclophosphamide, methotrexate, and fluorouracil (CMF). Hormonal therapy consists of tamoxifen or ovarian ablation (either surgical or chemical).

the combination of chemotherapy and tamoxifen is recommended, especially for women with a high risk of recurrent disease. There is substantial agreement about the choice of optimal adjuvant therapy once it has been determined that a woman might benefit from this intervention (Table 4).

Dose-Intensive and High-Dose Chemotherapy Regimens

In dose-intensive regimens, chemotherapy is administered in conventional doses but at shorter intervals; in high-dose regimens, chemotherapy is given in doses higher than conventional doses. Although preliminary results with these regimens are encouraging, there is no evidence from randomized trials that either type of regimen is more effective than standard-dose adjuvant chemotherapy or than chemotherapy and hormonal therapy combined. Ongoing randomized trials should help to determine the efficacy of high-dose regimens and new therapeutic agents as curative treatments in breast cancer.^{61,62}

Locally Advanced and Inflammatory Breast Cancer

Stage III breast cancer includes tumors larger than 5 cm in the largest diameter, tumors of any size with direct invasion of the skin of the breast or the chest wall, and any tumors with fixed or matted axillary lymphadenopathy. Women with stage III or locally advanced breast cancer should be treated with preoperative chemotherapy or hormonal therapy, surgery, and radiotherapy.^{63,64} In more than 65 percent of such women, the tumors shrink by more than 50

percent with preoperative chemotherapy. Most previously inoperable tumors become operable, and some become amenable to breast-conserving therapy.⁶⁴ Limited data suggest that adjuvant chemotherapy and hormonal therapy are indicated after preoperative chemotherapy and regional treatment.⁶⁵ Excellent local control can be achieved in 80 to 90 percent of women, and about 30 percent of women with stage IIIB tumors (tumors with direct invasion of the skin of the breast or the chest wall) or inflammatory breast cancer remain free of cancer after 10 years.^{63,66}

Metastatic Breast Cancer

The clinical course of metastatic breast cancer is variable; this heterogeneity results in large variations in growth rate and responsiveness to systemic therapy. Chemotherapy, hormonal therapy, radiotherapy, and limited surgery are all used in the treatment of women with metastatic breast cancer,⁶⁷ although the overwhelming majority of these women will die of their disease.⁶⁸ Therefore, optimal palliation and prolongation of life are the main goals of treatment. It is important to use all available treatments to obtain maximal control of symptoms, prevent serious complications, and prolong life with minimal disruption of the woman's lifestyle and quality of life (Fig. 2).

Diagnosis

Frequent testing to identify recurrences and metastases in order to institute aggressive treatment has not altered the clinical course of women with meta-

TABLE 4. SELECTION OF ADJUVANT SYSTEMIC THERAPY FOR WOMEN WITH OPERABLE PRIMARY BREAST CANCER AND INDICATIONS FOR ADJUVANT TREATMENT.

CHARACTERISTICS OF PATIENT AND TUMOR		LEVEL OF RISK	ADJUVANT SYSTEMIC THERAPY*
AGE	ESTROGEN-RECEPTOR STATUS		
<50 yr	Negative	Any	Chemotherapy
	Positive	Low	Hormonal therapy or Chemotherapy
≥50 yr	Positive	Moderate or high	Chemotherapy and hormonal therapy
			Chemotherapy and hormonal therapy or Investigational therapies
	Unknown	Any	Chemotherapy and hormonal therapy
			Chemotherapy or Tamoxifen
Positive	Moderate or high	Chemotherapy and hormonal therapy	
		Chemotherapy and hormonal therapy or Investigational therapies	
Unknown	Any	Chemotherapy and hormonal therapy	

*Chemotherapy consists of fluorouracil, doxorubicin, and cyclophosphamide (FAC); doxorubicin and cyclophosphamide (AC); or cyclophosphamide, methotrexate, and fluorouracil (CMF). Hormonal therapy consists of tamoxifen or ovarian ablation (either surgical or chemical).




Figure 2. Optimal Palliative Therapy for Women with Metastatic Breast Cancer.

static breast cancer. Most recurrences or metastases are diagnosed on the basis of symptoms and physical findings, and extensive biochemical testing or imaging contributes little.^{69,70} Guidelines for surveillance of asymptomatic women are shown in Table 5.⁷¹

Treatment

Once metastatic breast cancer becomes evident, it is appropriate to determine the extent and location of metastases. An overall therapeutic strategy is then developed on the basis of age, disease-free interval, hormone-receptor status, and extent of disease. For

women with limited and non-life-threatening disease, especially those who have no symptoms, are elderly, or have estrogen-receptor-positive tumors, hormonal therapy is the initial treatment of choice (Fig. 2).^{66,72} There has been a quiet revolution in hormonal therapy. Ablative endocrine procedures have been replaced by specific, well-tolerated hormonal treatments (antiestrogens, aromatase inhibitors, gonadotropin-releasing-hormone analogues, and progestins) (Table 6). Women who have a response to one hormonal intervention often have a response to a second after the first becomes ineffective.⁷² Some women may thus

TABLE 5. GUIDELINES FOR SURVEILLANCE OF WOMEN WITH OPERABLE BREAST CANCER AFTER THE COMPLETION OF PRIMARY TREATMENT.*

PROCEDURE	FREQUENCY
Education of patient about symptoms and signs of recurrence	At the completion of therapy and as needed
History and physical examination	Every 3 to 6 months for the first 3 years, every 6 to 12 months for the next 2 years, then annually
Breast self-examination	Monthly
Mammography	
Contralateral	Annually
Ipsilateral (remaining breast after lumpectomy)	Annually
Other recommended cancer-screening procedures†	Annually or every 2 years
Complete blood count, automated blood-chemistry studies, assays for serum tumor markers (carcino-embryonic antigen, CA2729, CA15-3)	Not recommended
Radionuclide bone scanning; imaging of the chest, abdomen, pelvis, or brain	Not recommended

*Guidelines are from the American Society of Clinical Oncology.⁷¹

†Other recommended procedures are pelvic examination with Pap smear, rectal examination, fecal occult-blood testing, and examination of the skin.

benefit from three or four hormonal therapies in sequence and have a good quality of life with minimal symptoms and side effects for several years. Twenty to 35 percent of women with metastatic breast cancer have an objective response to the initial hormonal therapy.^{72,73} For second-line hormonal treatment of women with receptor-positive tumors, the probability of an objective response ranges from 10 percent to 20 percent,⁷⁴ and another 15 to 30 percent of women may have stable disease for six months or longer. Table 6 describes the preferred sequence of current hormonal options.

Eventually, in most women, metastatic breast cancer becomes refractory to hormonal treatment, at which time the women should receive chemotherapy (CMF or FAC). Fifty to 80 percent of women have an objective response to FAC, and 40 to 60 percent have an objective response to CMF.⁷⁵ Both regimens provide substantial palliation with tolerable levels of

toxicity. In a recent meta-analysis of randomized trials, anthracycline-containing combinations were superior to CMF.⁷⁶ In the past 10 years, several new drugs have become available for the management of breast cancer (Table 7).^{62,67} Among these, vinorelbine, a third-generation vinca alkaloid,⁷⁷ and the taxanes (paclitaxel and docetaxel)⁷⁸ are the most prominent. Vinorelbine, paclitaxel, and docetaxel given alone result in response rates similar to those associated with CMF as first-line treatment. Combinations of taxanes and anthracyclines result in responses in 40 to 94 percent of women in first-line treatment and complete remissions in 12 to 41 percent.⁷⁹ The durations of remission and times to progression after treatment with doxorubicin–paclitaxel or doxorubicin–docetaxel combinations are similar to those after therapy with CMF or FAC.

The approach to metastatic breast cancer that progresses after hormonal therapy followed by first-line chemotherapy is changing rapidly.⁸⁰⁻⁸² Today, the taxanes and vinorelbine are the second-line and third-line treatments of choice, respectively, and we know that taxane-containing salvage regimens improve overall survival.^{81,82} Another area of progress has been the treatment of anthracycline-resistant breast cancer, defined as disease that progresses during treatment with a regimen containing an anthracycline (doxorubicin or a related drug). Before taxanes became available, the response rates in women with tumors resistant to anthracyclines (as second-line or third-line treatment) were less than 10 percent, and their overall survival was less than six months. Now, with the availability of taxanes, the response rates in these women range from 30 percent to 40 percent and survival for 10 to 12 months is customary.^{81,83,84}

TABLE 6. HORMONAL THERAPIES FOR WOMEN WITH METASTATIC BREAST CANCER.

ORDER OF THERAPY	PREMENOPAUSAL WOMEN	POSTMENOPAUSAL WOMEN
First line	Antiestrogens or ovarian ablation (chemical, surgical, or postradiation)	Antiestrogens
Second line	Ovarian ablation after antiestrogens; antiestrogens after ovarian ablation	Aromatase inhibitors
Third line	Progestins	Progestins
Fourth line	Androgens	Androgens or estrogens

TABLE 7. NEW AGENTS FOR SYSTEMIC THERAPY IN WOMEN WITH METASTATIC BREAST CANCER.*

AGENT	STAGE OF CLINICAL DEVELOPMENT	RESPONSE RATE
		%
Hormonal		
Antiestrogens		
Toremifene (Fareston)	Commercially available	19–54
Raloxifene (Evista)	Approved by the FDA for osteoporosis; in phase 3 trials	
Idoxifene	In phase 3 trials for metastatic breast cancer	12–39
Faslodex (ICI 182,780)	In phase 3 trials for metastatic breast cancer	
Aromatase inhibitors		
Formestane	Commercially available in Europe	12–39
Anastrozole (Arimidex)	Commercially available; in phase 3 trials	
Letrozole (Femara)	Commercially available; in phase 3 trials	
Vorozole	In phase 3 trials for metastatic breast cancer	
Exemestane	In phase 3 trials for metastatic breast cancer	
Cytotoxic		
Anthracyclines		
Anthrapyrazoles		18–63
Losoxantrone	In phase 3 trials for metastatic breast cancer	
Anthracyclines		
Liposomal doxorubicin (D 99)	In phase 3 trials for metastatic breast cancer	18–33
Purine analogues		
Gemcitabine (Gemzar)	Commercially available for pancreatic cancer; in phase 3 trials for metastatic breast cancer	25–46
Taxanes		
Docetaxel (Taxotere)	Commercially available; in phase 3 trials as adjuvant therapy and for metastatic breast cancer	13–68
Paclitaxel (Taxol)	Commercially available; in phase 3 trials as adjuvant therapy and for metastatic breast cancer	
Thymidylate synthase inhibitors		
Capecitabine	Commercially available; in phase 3 trials for metastatic breast cancer	20–36
Raltitrexed (Tomudex)	In phase 3 trials for metastatic breast cancer	
UFT	In phase 3 trials for metastatic breast cancer	
Vinca alkaloids		
Vinorelbine (Navelbine)	Commercially available for lung cancer; in phase 3 trials as adjuvant therapy and for metastatic breast cancer	18–52

*FDA denotes Food and Drug Administration, and UFT uracil–ftorafur.

Bone is the most common site of metastases in breast cancer, and bone metastases are the cause of substantial morbidity and complications. Bisphosphonates (pamidronate and clodronate [clodronic acid]) added to chemotherapy or hormonal therapy reduce pain and the incidence of complications, and they prolong survival free of bone-related events.⁸⁵

High-Dose Chemotherapy

The development of techniques to harvest, store, and reinfuse autologous hematopoietic stem cells and the availability of hematopoietic growth factors have allowed the evaluation of very-high-dose chemotherapeutic regimens (given at doses 2 to 20 times as high as standard doses).^{86,87} Two types of high-dose regimens have been studied. In one, a single cycle of a high-dose combination of cytotoxic drugs (usually alkylating agents) is administered, which ablates the bone marrow. The purpose of treatment is not to destroy normal bone marrow, but to give the highest tolerable doses of chemotherapy in the hope of killing the highest possible number of breast-cancer cells.

Bone marrow damage is the earliest limiting toxic effect of most alkylating agents; this effect can be eliminated or lessened by harvesting autologous hematopoietic stem cells and reinfusing them after the administration of high-dose chemotherapy to repopulate normal bone marrow. In the second type of regimen, two to four cycles of cytotoxic-drug combinations are administered at doses that are higher than usual but do not ablate the bone marrow. These high-dose regimens result in higher overall rates of remission, and especially of complete remission (in the range of 40 to 60 percent), in women with previously untreated metastatic breast cancer, and 15 to 25 percent of women remain free of cancer for three to five years.⁸⁷⁻⁸⁹ However, there is no evidence that such therapy results in any better palliation in women with refractory breast cancer than that obtained with standard-dose chemotherapy. In the absence of comparative trials, it is uncertain whether the 15 to 25 percent rate of long-term cancer-free survival is the result of high-dose therapy or simply a consequence of the selection of patients,⁹⁰ although in one small,

randomized trial, high-dose therapy resulted in better progression-free survival and overall survival than standard-dose therapy.⁹¹

CHEMOPREVENTION

The administration of adjuvant tamoxifen for five years after primary therapy reduces the incidence of contralateral breast cancer by 47 percent.⁵⁴ In a recently completed randomized study, more than 13,000 women at high risk for breast cancer received daily tamoxifen (20 mg) or placebo. After a mean follow-up of 3.5 years, there was a 45 percent decrease in the incidence of breast cancer in the tamoxifen group.⁹² Endometrial cancer developed in twice as many women in the tamoxifen group as in the placebo group. There was also an increase in thromboembolic events in the tamoxifen group. These adverse effects occurred predominantly in women older than 50 years. Overall, the beneficial effects of tamoxifen outweighed its adverse effects. The results of two other studies of chemoprevention with tamoxifen and one of fenretinide are not yet available.

NOVEL THERAPIES

Cytotoxic agents under development include anthracyclines,⁹³ liposomal anthracyclines,^{94,95} gemcitabine,⁹⁶ several novel anti-folic acid compounds,⁹⁷ and new thymidylate synthase inhibitors.⁹⁸ Among the new hormonal agents, pure antiestrogens,⁹⁹ aromatase inhibitors (anastrozole, letrozole, and vorozole),¹⁰⁰ and selective estrogen-receptor modulators^{101,102} are causing great excitement. One of the latter, raloxifene, approved for the treatment of osteoporosis, was associated with a reduction of more than 50 percent in the incidence of breast cancer in a recent randomized trial.¹⁰³

An increased understanding of the biology of breast cancer has led to the identification of novel therapeutic targets. For example, the HER-2/*neu* oncogene is overexpressed in 20 to 30 percent of breast cancers, and these tumors are more aggressive and somewhat more resistant to chemotherapy than those not overexpressing the oncogene.¹⁰⁴ Thirteen percent of women with metastatic breast cancer overexpressing HER-2/*neu* had objective responses to weekly injections of monoclonal antibodies against the extracellular domain of the HER-2/*neu* oncoprotein.¹⁰⁵ When the antibody was administered with cisplatin, the overall response rate was 25 percent, and some of the responses lasted for more than one year. In a recently completed randomized trial in which chemotherapy was combined with the anti-HER-2/*neu* antibody, a doubling or tripling of the response rate, a prolongation of the time to disease progression, and increased overall survival were observed in patients who received the combination therapy as compared with those patients receiving chemotherapy alone.¹⁰⁶

CONCLUSIONS

Marked progress has been made in the past 30 years in our understanding of breast cancer. The biologic behavior of this cancer, risk factors, and prognostic factors have been better characterized. We have identified several molecular genetic abnormalities that are associated with the development of invasive breast cancer and others that are correlated with its metastatic potential or response to treatment. The efficacy of our diagnostic and therapeutic approaches has improved, resulting in decreased mortality and in improved palliation for women for whom cure is not a possibility. Early diagnosis of primary breast cancer reduces the risk of death by 30 percent. Most patients with primary breast cancer can be optimally treated with breast-conserving local treatments, and the addition of systemic hormone therapy and chemotherapy reduces the risk of death by 25 to 50 percent. We have successfully taken the first steps in breast-cancer prevention and have developed several new drugs that are more effective and less toxic than the previous generation of antitumor agents.

REFERENCES

- Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer. *N Engl J Med* 1992;327:319-28, 390-8, 473-80.
- Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. *CA Cancer J Clin* 1997;47:5-27. [Erratum, *CA Cancer J Clin* 1997;47:68.]
- Chu KC, Tarone RE, Kessler LG, et al. Recent trends in U.S. breast cancer incidence, survival, and mortality rates. *J Natl Cancer Inst* 1996;88:1571-9.
- Garne JP, Aspegren K, Balldin G, Ranstam J. Increasing incidence of and declining mortality from breast carcinoma: trends in Malmo, Sweden, 1961-1992. *Cancer* 1997;79:69-74.
- Beral V, Hermon C, Reeves G, Peto R. Sudden fall in breast cancer death rates in England and Wales. *Lancet* 1995;345:1642-3.
- Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN. Proportion of breast cancer cases in the United States explained by well-established risk factors. *J Natl Cancer Inst* 1995;87:1681-5.
- Colditz GA. Epidemiology of breast cancer: findings from the Nurses' Health Study. *Cancer* 1993;71:Suppl:1480-9.
- Page DL, Dupont WD. Premalignant conditions and markers of elevated risk in the breast and their management. *Surg Clin North Am* 1990;70:831-51.
- Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. *N Engl J Med* 1985;312:146-51.
- Anderson DE. Familial versus sporadic breast cancer. *Cancer* 1992;70:Suppl:1740-6.
- King MC, Rowell S, Love SM. Inherited breast and ovarian cancer: what are the risks? What are the choices? *JAMA* 1993;269:1975-80.
- Eng C, Stratton M, Ponder B, et al. Familial cancer syndromes. *Lancet* 1994;343:709-13. [Erratum, *Lancet* 1994;343:926.]
- Colditz GA, Willett WC, Hunter DJ, et al. Family history, age, and risk of breast cancer: prospective data from the Nurses' Health Study. *JAMA* 1993;270:338-43. [Erratum, *JAMA* 1993;270:1548.]
- Casey G. The BRCA1 and BRCA2 breast cancer genes. *Curr Opin Oncol* 1997;9:88-93.
- Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. *Cancer* 1996;77:697-709.
- Hoskins KF, Stopfer JE, Calzone KA, et al. Assessment and counseling for women with a family history of breast cancer: a guide for clinicians. *JAMA* 1995;273:577-85.
- Brenner AJ, Aldaz CM. The genetics of sporadic breast cancer. *Prog Clin Biol Res* 1997;396:63-82.
- McKenzie K, Sukumar S. Molecular genetics of human breast cancer. *Prog Clin Biol Res* 1996;394:183-209.
- Dickson RB, Lippman ME. Growth factors in breast cancer. *Endocr Rev* 1995;16:559-89.
- Theriault RL. Medical treatment of bone metastases. In: Harris JR,

- Lippman ME, Morrow M, Hellman S, eds. Diseases of the breast. Philadelphia: Lippincott-Raven, 1996:819-26.
21. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? *J Natl Cancer Inst* 1997;89:21-39.
 22. Walker RA, Jones JL, Chappell S, Walsh T, Shaw JA. Molecular pathology of breast cancer and its application to clinical management. *Cancer Metastasis Rev* 1997;16:5-27.
 23. Engels K, Fox SB, Harris AL. Angiogenesis as a biologic and prognostic indicator in human breast carcinoma. *EXS* 1997;79:113-56.
 24. Teicher BA. Angiogenesis and cancer metastases: therapeutic approaches. *Crit Rev Oncol Hematol* 1995;20:9-39.
 25. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography: a meta-analysis. *JAMA* 1995;273:149-54.
 26. Breast cancer screening for women ages 40-49. NIH consensus statement. Vol. 15. No. 1. Bethesda, Md.: Office of Medical Applications of Research, 1997:1-35.
 27. Leitch AM, Dodd GD, Costanza M, et al. American Cancer Society guidelines for the early detection of breast cancer: update 1997. *CA Cancer J Clin* 1997;47:150-3.
 28. Khalkhali I, Mena I, Diggles L. Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m sestamibi. *Eur J Nucl Med* 1994;21:357-62.
 29. Hall FM. Technologic advances in breast imaging: current and future strategies, controversies, and opportunities. *Surg Oncol Clin North Am* 1997;6:403-9.
 30. Ciatto S, Cariaggi P, Bulgaresi P, Confortini M, Bonardi R. Fine needle aspiration cytology of the breast: review of 9533 consecutive cases. *Breast* 1993;2:87-90.
 31. Ballo MS, Sneige N. Can core needle biopsy replace fine-needle aspiration cytology in the diagnosis of palpable breast carcinoma: a comparative study of 124 women. *Cancer* 1996;78:773-7.
 32. Meyer JE, Christian RL, Lester SC, et al. Evaluation of nonpalpable solid breast masses with stereotaxic large-needle core biopsy using a dedicated unit. *AJR Am J Roentgenol* 1996;167:179-82.
 33. D'Angelo PC, Galliano DE, Rosemurgy AS. Stereotactic excisional breast biopsies utilizing the advanced breast biopsy instrumentation system. *Am J Surg* 1997;174:297-302.
 34. Treatment of early-stage breast cancer. *JAMA* 1991;265:391-5.
 35. Fisher B. Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer. *Cancer* 1977;40:Suppl:574-87.
 36. Tabar L, Fagerberg G, Day NE, Duffy SW, Kitchin RM. Breast cancer treatment and natural history: new insights from results of screening. *Lancet* 1992;339:412-4.
 37. Wilson RE, Donegan WL, Mettlin C, Natarajan N, Smart CR, Murphy GP. The 1982 national survey of carcinoma of the breast in the United States by the American College of Surgeons. *Surg Gynecol Obstet* 1984;159:309-18.
 38. Morris AD, Morris RD, Wilson JF, et al. Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival. *Cancer J Sci Am* 1997;3:6-12.
 39. Farrow DC, Hunt WC, Samet JM. Geographic variation in the treatment of localized breast cancer. *N Engl J Med* 1992;326:1097-101.
 40. Hand R, Sener S, Imperato J, Chmiel JS, Sylvester JA, Fremgen A. Hospital variables associated with quality of care for breast cancer patients. *JAMA* 1991;266:3429-32.
 41. Solin LJ, Kurtz J, Fourquet A, et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. *J Clin Oncol* 1996;14:754-63.
 42. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. *J Clin Oncol* 1998;16:441-52.
 43. Cady B. Is axillary lymph node dissection necessary in routine management of breast cancer? No. *Important Adv Oncol* 1996;251-65.
 44. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. *J Clin Oncol* 1997;15:2345-50.
 45. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer: a multicenter validation study. *N Engl J Med* 1998;339:941-6.
 46. Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. *N Engl J Med* 1996;334:1356-61.
 47. Cuzick J, Stewart H, Peto R, et al. Overview of randomized trials comparing radical mastectomy without radiotherapy against simple mastectomy with radiotherapy in breast cancer. *Cancer Treat Rep* 1987;71:7-14.
 48. Cuzick J, Stewart H, Peto R, et al. Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. *Cancer Treat Rep* 1987;71:15-29.
 49. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. *N Engl J Med* 1995;333:1444-55. [Erratum, *N Engl J Med* 1996;334:1003.]
 50. Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. *J Clin Oncol* 1994;12:447-53.
 51. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. *N Engl J Med* 1997;337:956-62.
 52. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. *N Engl J Med* 1997;337:949-55.
 53. Hortobagyi GN, Buzdar AU. Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. *CA Cancer J Clin* 1995;45:199-226.
 54. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. *Lancet* 1998;351:1451-67.
 55. *Idem*. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. *Lancet* 1992;339:71-85.
 56. *Idem*. Ovarian ablation in early breast cancer: overview of the randomised trials. *Lancet* 1996;348:1189-96.
 57. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. *J Natl Cancer Inst* 1996;88:1529-42.
 58. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. *J Clin Oncol* 1997;15:2483-93.
 59. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. *Lancet* 1992;339:1-15.
 60. Henderson IC, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S, et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. *Proc Am Soc Clin Oncol* 1998;17:101a. abstract.
 61. Hortobagyi GN. Paclitaxel-based combination chemotherapy for breast cancer. *Oncology (Huntingt)* 1997;11:29-37. [Erratum, *Oncology (Huntingt)* 1997;11:943.]
 62. Hortobagyi GN, Ibrahim N. Combinations of new and old agents for breast cancer treatment: future directions. *Oncology (Huntingt)* 1996;10:Suppl:30-6.
 63. Hortobagyi GN, Singletary SE, McNeese MD. Treatment of locally advanced and inflammatory breast cancer. In: Harris JR, Lippman ME, Morrow M, Hellman S, eds. Diseases of the breast. Philadelphia: Lippincott-Raven, 1996:585-99.
 64. Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. *Cancer* 1994;74:Suppl:416-23.
 65. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. *Cancer Chemother Pharmacol* 1978;1:53-9.
 66. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. *J Clin Oncol* 1992;10:1014-24.
 67. Hortobagyi GN, Piccart-Gebhart MJ. Current management of advanced breast cancer. *Semin Oncol* 1996;23:Suppl 11:1-5.
 68. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. *J Clin Oncol* 1996;14:2197-205.
 69. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial: National Research Council Project on Breast Cancer follow-up. *JAMA* 1994;271:1593-7.
 70. The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized clinical trial. *JAMA* 1994;271:1587-92.
 71. Recommended breast cancer surveillance guidelines: American Society of Clinical Oncology. *J Clin Oncol* 1997;15:2149-56.
 72. Hortobagyi GN. Endocrine treatment of breast cancer. In: Becker KL, ed. Principles and practice of endocrinology and metabolism. 2nd ed. Philadelphia: J.B. Lippincott, 1995:1868-75.
 73. Stuart NS, Warwick J, Blackledge GR, et al. A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer. *Eur J Cancer* 1996;32A:1888-92.
 74. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal

- women with advanced breast carcinoma: Arimidex Study Group. *Cancer* 1997;79:730-9.
- 75.** Henderson IC. Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson IC, Kinne DW, eds. *Breast diseases*. 2nd ed. Philadelphia: J.B. Lippincott, 1991:604-65.
- 76.** A'Hern RP, Smith IE, Ebbs SR. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. *Br J Cancer* 1993;67:801-5.
- 77.** Johnson SA, Harper P, Hortobagyi GN, Pouillart P. Vinorelbine: an overview. *Cancer Treat Rev* 1996;22:127-42.
- 78.** Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. *Ann Oncol* 1994;5:495-505.
- 79.** Hortobagyi GN, Holmes FA. Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer. *Semin Oncol* 1997;24:Suppl 3:S4-S7.
- 80.** Hortobagyi GN. Salvage chemotherapy for metastatic breast cancer. *Semin Hematol* 1987;24:Suppl 1:56-61.
- 81.** Nabholz J, Thuerlimann B, Bezwoda WR, et al. Taxotere (T) versus mitomycin C+ vinblastine (MV) in patients (pts) with metastatic breast cancer (MBC) who have failed an anthracycline containing regimen: preliminary results of a randomized phase III study. *Proc Am Soc Clin Oncol* 1997;16:A519. abstract.
- 82.** Dieras V, Marty M, Tubiana N, et al. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer. *Semin Oncol* 1995;22:Suppl 8:33-9.
- 83.** Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. *J Clin Oncol* 1995;13:2886-94.
- 84.** Nabholz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. *J Clin Oncol* 1996;14:1858-67.
- 85.** Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. *N Engl J Med* 1996;335:1785-91.
- 86.** Henderson IC, Hayes DF, Gelman R. Dose-response in the treatment of breast cancer: a critical review. *J Clin Oncol* 1988;6:1501-15.
- 87.** Vahdat L, Antman KH. Dose-intensive therapy in breast cancer. In: Armitage JO, Antman KH, eds. *High-dose cancer therapy: pharmacology, hematopoietins, stem cells*. 2nd ed. Baltimore: Williams & Wilkins, 1995: 802-23.
- 88.** Eddy DM. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. *J Clin Oncol* 1992;10:657-70. [Erratum, *J Clin Oncol* 1992;10:1655-8.]
- 89.** Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. *J Clin Oncol* 1997;15:1870-9.
- 90.** Rahman ZU, Frye DK, Buzdar AU, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. *J Clin Oncol* 1997;15:3171-7.
- 91.** Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. *J Clin Oncol* 1995;13:2483-9.
- 92.** Wickerham DL, Constantino J, Fisher B, et al. The initial results from NSABP protocol P-1: a clinical trial to determine the worth of tamoxifen for preventing breast cancer in women at increased risk. Presented at the 34th Annual Meeting of the American Society of Clinical Oncology Plenary Session, Los Angeles, May 16-19, 1998. abstract.
- 93.** Judson IR. The anthrapyrazoles: a new class of compounds with clinical activity in breast cancer. *Semin Oncol* 1992;19:687-94.
- 94.** Booser DJ, Hortobagyi GN. Anthracycline antibiotics in cancer therapy: focus on drug resistance. *Drugs* 1994;47:223-58.
- 95.** Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. *J Clin Oncol* 1997;15:3185-91.
- 96.** Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. *J Clin Oncol* 1995;13:2731-6.
- 97.** Schornagel JH, van der Veegt S, Verweij J, et al. Phase II study of edatrexate in chemotherapy-naïve patients with metastatic breast cancer. *Ann Oncol* 1992;3:549-52.
- 98.** Smith I, Jones A, Spielmann M, et al. A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. *Br J Cancer* 1996;74:479-81.
- 99.** Gradishar WJ, Jordan VC. Clinical potential of new antiestrogens. *J Clin Oncol* 1997;15:840-52.
- 100.** Ibrahim NK, Buzdar AU. Aromatase inhibitors: current status. *Am J Clin Oncol* 1995;18:407-17.
- 101.** Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. *N Engl J Med* 1997;337:1641-7.
- 102.** Howell A, Downey S, Anderson E. New endocrine therapies for breast cancer. *Eur J Cancer* 1996;32A:576-88.
- 103.** Cummings SR, Norton L, Eckert S, et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women: two-year findings from the Multiple Outcomes of Raloxifene Evaluation Trial. *Proc Am Soc Clin Oncol* 1998;17:2a. abstract.
- 104.** Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987;235:177-82.
- 105.** Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. *J Clin Oncol* 1996;14:737-44.
- 106.** Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial. *Proc Am Soc Clin Oncol* 1998;17:98a. abstract.